Feb 25 (Reuters) – Sarepta Therapeutics CEO Douglas Ingram has decided to step down by the end of 2026 or upon the appointment of his replacement, the company said in a regulatory filing.
The company said it has commenced a search for his replacement.
* The company had a tumultuous 2025 after its gene therapy,Elevidys, for a type of muscle disorder led to the deaths of twopatients and falling sales * The U.S. Food and Drug Administration last year askedSarepta to voluntarily halt shipments of Elevidys and said itwas investigating the deaths linked to the therapy * The company announced 500 job cuts and halted developmentof several gene therapies for limb-girdle muscular dystrophylast year * Elevidys’s label carries the U.S. health regulator’s mostserious safety warning, as well as stringent monitoringrequirements after treatment * Elevidys has emerged from a challenging year, CEO Ingramsaid on Wednesday, adding that the company is executing plans toput it on a potential pathway to make the treatment available tonon‑ambulatory patients * Shares of the company fell 82% last year * The stock was down about 4% in after-market trading onWednesday * Ingram has served as chief executive officer since 2017
(Reporting by Sneha S K; Editing by Shinjini Ganguli)
